Adoptive transfer of Wilms’s tumor 1 (WT1)-specific TCR-T has been tested in patients with refractory AML, high-risk MDS [83], and AML after allogeneic hematopoietic cell transplantation [84] (Table S2). Here, WT1 is linked to acute myeloid leukemia.